多肽CRDMO平台
目录肽
中肽生化目录肽版块全新呈现，致力于打造全球最全面的多肽供应平台！我们专业的学术团队将时刻追踪最新最热的研究动向，帮助您发现实际需求，并以最高质量标准提供您所需要的产品。我们将我们将不定期更新产品列表，为您最大限度地节约科研时间，敬请广大客户朋友关注！
LHRH-014A
Histrelin
Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt\nAcetate salt
Pyr-His-Trp-Ser-Tyr-D-His(Bzl)-Leu-Arg-Pro-NHEt\nAcetate salt
Size：5
P1(RMB)：2120
MW：1323.52
One letter sequence：Pyr-HWSYh(Bzl)-LRP-NHEt
Molecular Formula：C66H86N18O12
Description：As a potent LHRH agonist, histrelin stimulates LH and FSH release and inhibits the actions of sex steroids on the male and female reproductive tracts. Its potency in vivo and in vitro is similar to that of the D-Trp6-containing analog. Especially because of its high water solubility and greater lipophilic character, histrelin appears promising for clinical application.Slow-release implants containing histreline implants were approved for the palliative treatment of advanced hormone-dependent prostate cancer.
Literature Reference：K.Sundaram et al., Life Sci., 28, 83 (1981)\nJ.DeFazio et al., Endocr. Res., 10, 163 (1984)\nM.J.Gibson and D.S.Kohtz, Contraception, 31, 91 (1985)\nM.J.Karten and J.E.Rivier, Endocr. Rev., 7, 44 (1986)\nG.C.Doelle et al., Horm. Metab. Res., 18, 201 (1986)\nJ.W.Gunnet et al., J. Endocrinol., 131, 211 (1991)\nM.Montagner et al., Reprod. Fertil. Dev., 17, 222 (2005)\nMerck Index, 14th ed., No. 4722, (2006)\nE.D.Deeks, Drugs, 70, 623 (2010)\nN.Shore et al., BJU Int., 109, 226 (2012)
Cas：220810-26-4
P1(RMB)：2120
MW：1323.52
One letter sequence：Pyr-HWSYh(Bzl)-LRP-NHEt
Molecular Formula：C66H86N18O12
Description：As a potent LHRH agonist, histrelin stimulates LH and FSH release and inhibits the actions of sex steroids on the male and female reproductive tracts. Its potency in vivo and in vitro is similar to that of the D-Trp6-containing analog. Especially because of its high water solubility and greater lipophilic character, histrelin appears promising for clinical application.Slow-release implants containing histreline implants were approved for the palliative treatment of advanced hormone-dependent prostate cancer.
Literature Reference：K.Sundaram et al., Life Sci., 28, 83 (1981)\nJ.DeFazio et al., Endocr. Res., 10, 163 (1984)\nM.J.Gibson and D.S.Kohtz, Contraception, 31, 91 (1985)\nM.J.Karten and J.E.Rivier, Endocr. Rev., 7, 44 (1986)\nG.C.Doelle et al., Horm. Metab. Res., 18, 201 (1986)\nJ.W.Gunnet et al., J. Endocrinol., 131, 211 (1991)\nM.Montagner et al., Reprod. Fertil. Dev., 17, 222 (2005)\nMerck Index, 14th ed., No. 4722, (2006)\nE.D.Deeks, Drugs, 70, 623 (2010)\nN.Shore et al., BJU Int., 109, 226 (2012)
Cas：220810-26-4
